Calcimimetics: Therapeutic potential in hyperparathyroidism

Current Opinion in Pharmacology

Volumn 2, Issue 6, 2002, Pages 734-739

  Cohen, Adi ^a   Silverberg, Shonni J ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; CALCIUM; CALCIUM SENSING RECEPTOR; CELL SURFACE RECEPTOR; CINACALCET; N (2 CHLOROPHENYLPROPYL) 1 (3 METHOXYPHENYL)ETHYLAMINE; N-(2-CHLOROPHENYLPROPYL)-1-(3-METHOXYPHENYL)ETHYLAMINE; NAPHTHALENE DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM ANTAGONIST; CALCIUM CHANNEL STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PHENYLALKYLAMINE; PHOSPHATE BINDING AGENT; R 568; UNCLASSIFIED DRUG; VITAMIN D;

DRUG POTENTIATION; HOMEOSTASIS; HUMAN; HYPERPARATHYROIDISM; METABOLISM; MOLECULAR MIMICRY; REVIEW; CALCITONIN BLOOD LEVEL; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; ELECTROLYTE DISTURBANCE; EXTRACELLULAR CALCIUM; HYPOCALCEMIA; NONHUMAN; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL;

ANILINE COMPOUNDS; CALCIUM; HOMEOSTASIS; HUMANS; HYPERPARATHYROIDISM; MOLECULAR MIMICRY; NAPHTHALENES; RECEPTORS, CALCIUM-SENSING; RECEPTORS, CELL SURFACE;

EID: 0036904133     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00210-2     Document Type: Review

References (42)

1. Brown EM: Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am J Med 1999, 106:238-253.
2. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993, 366:575-580.
3. Garrett JE, Capuano IV, Hammerland LG, Hung BC, Brown EM, Hebert SC, Nemeth EF, Fuller F: Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 1995, 270:12919-12925.
4. Brown EM, Pollak M, Seidman CE, Seidman JG, Chou YH, Riccardi D, Hebert SC: Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995, 333:234-240.
5. Coburn JW, Elangovan L, Goodman WG, Frazao JM: Calciumsensing receptor and calcimimetic agents. Kidney Int Suppl 1999, 73:S52-58.
6. Chattopadhyay N: Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor. Int J Biochem Cell Biol 2000, 32:789-804.
7. 2+ receptors. Mol Pharmacol 1999, 55:642-648.
8. Garrett JE, Tamir H, Kifor O, Simin RT, Rogers KV, Mithal A, Gagel RF, Brown EM: Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 1995, 136:5202-5211.
9. Freichel M, Zink-Lorenz A, Holloschi A, Hafner M, Flockerzi V, Raue F: Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion. Endocrinology 1996, 137:3842-3848.
10. 2+/polyvalent cation-sensing protein in rat kidney. Am J Physiol 1998, 274:F611-622.
11. Hebert SC, Brown EM, Harris HW: Role of the Ca(2+)-sensing receptor in divalent mineral ion homeostasis. J Exp Biol 1997, 200:295-302.
12. Brown EM: Mutations in the calcium-sensing receptor and their clinical implications. Horm Res 1997, 48:199-208.
13. Pollak MR, Chou YH, Marx SJ, Steinmann B, Cole DE, Brandi ML, Papapoulos SE, Menko FH, Hendy GN, Brown EM et al.: Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 1994, 93:1108-1112.
14. Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG: Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993, 75:1297-1303.
15. Pearce SH, Trump D, Wooding C, Besser GM, Chew SL, Grant DB, Heath DA, Hughes IA, Paterson CR, Whyte MP et al.: Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest 1995, 96:2683-2692.
16. Attie MF, Gill JR Jr, Stock JL, Spiegel AM, Downs RW Jr, Levine MA, Marx SJ: Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism. J Clin Invest 1983, 72:667-676.
17. Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, Hebert SC, Seidman CE, Seidman JG: Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 1994, 8:303-307.
18. Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB Jr: Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Hum Mol Genet 1996, 5:601-606.
19. Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P et al.: A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996, 335:1115-1122.
20. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81:1598-1606.
21. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997, 51:328-336.
22. Nemeth EF, Fox J: Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 1999, 10:66-71.
23. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998, 95:4040-4045.
24. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 1998, 53:1083-1088.
25. Steffey ME, Fox J, VanWagenen BC, DelMar EG, Balandrin MF, Nemeth EF: Calcimimetics: structurally and mechanistically novel compounds that inhibit hormone secretion from parathyroid cells. J Bone Mineral Res (Abstract) 1993, 8(Suppl 1):S175.
26. Fox J, Lowe SH, Petty BA, Nemeth EF: NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999, 290:473-479.
27. Fox J, Lowe SH, Conklin RL, Petty BA, Nemeth EF: Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J Pharmacol Exp Ther 1999, 290:480-486.
28. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997, 100:2977-2983.
29. Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J: Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 2000, 11:903-911.
30. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000, 57:50-58.
31. Ishii H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J: Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low- turnover bone and osteomalacia. Bone 2000, 26:175-182.
32. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998, 53:448-453.
33. Heath HI, Sanguinetti EL, Ogelsby S, Marriott TB: Inhibition of human parathyroid hormone secretion in vivo by NPS R-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor. Bone 1995, 16:85S.
34. Silverberg SJ, Bone HG III, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EL, Bilezikian JP: Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997, 337:1506-1510.
35. Akizawa T, Suzuki M, Tominaga Y, Saito A, Uchida E, Kawaguchi Y, Ogata E, Kurokawa K: Acute effects of calcimimetic agent (CA) on hemodialysis (HD) patients with secondary hyperparathyroidism (2HPT). Am J Soc Nephrol 1998, 9:561A.
36. Antonsen JE, Sherrard DJ, Andress DL: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 1998, 53:223-227.
37. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000, 58:436-445.
38. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998, 83:1083-1088.
39. Shoback DM, Firek AF, Mims RB, Binder TA, Graves T, Turner SA, Peacock M: An evaluation of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism (PHPT). J Bone Mineral Res (Abstract) 2001:S303.
40. Peacock M, Shoback DM, Greth E, Binder TA, Graves T, Brenner RM, Turner SA: The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism (PHPT). J Bone Mineral Res (Abstract) 2001:S163.
41. Peacock M, Bilezikian J, Turner SA, Guo MD, McCary LC, Koenig KG, Shoback DM: Long-term treatment with the calcimimetic AMG 073 in patients with primary hyperparathyroidism (PHPT), Abstract OR21-1. The Endocrine Society 84th Annual Meeting, 19-22 June 2002, San Francisco CA.
42. Peacock M: Normalization of hypercalcemia with the calcimimetic AMG073 in a patient with metastatic parathyroid cancer. J Bone Mineral Res 2002, 17:S381.